Spinal Cord Injury Research

Clinical Trials

Updated 2/20/2013
Search for Clinical Trials using ClinicalTrials.gov

Clinical Trials

Autologous Bone Marrow Stem Cell Transplantation in Patients With Spinal Cord Injury
Hospital Sao Rafael. The aim of this study is to evaluate autologous bone marrow stem cells transplantation as a safe and potentially beneficial treatment for patients with spinal cord injury.

StemCells Inc.
Phase I/II clinical trial of HuCNS-SC cells in chronic spinal cord injury. The trial initiated in March 2011 and is currently open for enrollment. The trial is being conducted in Switzerland at the Balgrist University Hospital, University of Zurich Clinical Trial Info

ReNeuron Group
REN001 stem cell therapy for ischaemic stroke. ReNeuron stroke clinical trial cleared to dose remaining patients - first patient in final dose cohort treated
Spinal Cord Injury Network USA (SCINetUSA)
SCINetUSA evolved from the efforts of Dr. Wise Young of Rutgers University after his successful establishment of ChinaSCINet clinical trials network.  You can help support the SCINetUSA trial by visiting Just a Dollar Please website.

China Spinal Cord Injury Network Multiple trial for the treatment of chronic spinal cord injuries. Dr. Wise Young from Rutgers University is involved with these trials.
Clinical Trial Info

Novartis ATI355 in Patients With Acute Spinal Cord Injury. Trial has completed. Clinical Trial Info

Geron Corporation announced the company's plan to for clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury has been halted due to financial issues.

GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein (MAG), a protein that inhibits axonal regeneration. GSK249320 acts as a MAG antagonist, and through this activity it is hypothesised that it will enhance recovery from neuronal degeneration following acute axonal injury, which occurs in spinal cord injury or stroke. This study is now completed.

Alseres Pharmaceuticals
Cethrin - for the treatment of acute spinal cord injury. The phase I/II trial has been completed and Cethrin was well tolerated. A phase II trial is currently planned to start in October 2009.
Novagenesis' RMx regenerative matrix been in development for several years but has yet to move into clinical trials. The company has not released any new information about its plans and it is uncertain if or when they will be ready to initiate clinical trials.

XenoProt arbaclofen placarbil (AP) is being developed as a potential treatment for patients with spasticity.Clinical Trial Info

Allegan is conductiong a clinical trial for the safety and efficacy of botulinum toxin type A (Botox) for the treatment of neurogenic overactive bladder in patients with a spinal cord injury or multiple sclerosis. Additionally, a long term followup clinical trial of botulinum toxin type A (Botox) for neurogenic overactive bladder is also being conducted. Clinical Trial Info

Safety of Riluzole in Patients With Acute Spinal Cord Injury
The primary aim of the study is to develop acute care safety and pharmacokinetic profiles of riluzole in patients who have sustained a acute traumatic spinal cord injury. Secondary objectives are to conduct exploratory analyses of functional outcomes for purposes of planning a subsequent Phase II randomized study of the efficiency of Riluzole for the treatment of acute traumatic spinal cord injury.

Taipei Veterans General Hospital-Interpositional nerve grafts in combination with fibroblast growth factor (FGF).
This trial is the result of an initial phase 1 human clinical trial involving fibroblast growth factors used alone in patients with cervical spinal cord injury. According to the author of this paper, a study involving FGF and nerve grafts is ongoing at Taipei Veterans General Hospital. This study involves patients with completely transected spinal cords.